506186812 08/04/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6233551

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
PETER KASTNER	03/30/2020

RECEIVING PARTY DATA

Name:	ROCHE DIAGNOSTICS GMBH	
Street Address:	SANDHOFER STRASSE 116	
City:	MANNHEIM	
State/Country:	GERMANY	
Postal Code:	68305	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15943104

CORRESPONDENCE DATA

Fax Number: (317)521-2883

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 317-521-3104

Email: jackie.pike@roche.com
Correspondent Name: KENNETH J. WAITE
Address Line 1: 9115 HAGUE ROAD

Address Line 4: INDIANAPOLIS, INDIANA 46250

ATTORNEY DOCKET NUMBER:	P33022-US-CPS
NAME OF SUBMITTER:	KENNETH J. WAITE
SIGNATURE:	/Kenneth J. Waite/
DATE SIGNED:	08/04/2020

Total Attachments: 2

source=Assignment Inventor-RDG#page1.tif source=Assignment Inventor-RDG#page2.tif

PATENT 506186812 REEL: 054106 FRAME: 0318

ASSIGNMENT AGREEMENT

I/We, the undersigned

Inventor(s)

Employed by:

1.Peter KASTNER, a German citizen,

Aufeld 7

82418 Murnau am Staffelsee

Germany

Roche Diagnostics GmbH

hereinafter ASSIGNOR(S), herewith declare that I am/we are joint inventor(s) together with

Inventor(s)

Anna Edelgard KAISER

Employedby:

Roche Diagnostics International

AG

hereinafter CO-INVENTOR(S)

of the invention entitled:

IGFBP7 for prediction of risk of AKI when measured prior to surgery

for which (a) priority application(s) was (were) filed with the

Patent Office

European Patent Office

as outlined below:

Case No.

Country

Filing Date

Serial No.

P33022

PCT

October 10, 2016

PCT/EP2016/074206

ASSIGNOR(S) acknowledge(s) the previous transfer to

Roche Diagnostics GmbH Sandhofer Strasse 116 68305 Mannheim Germany

hereinafter ASSIGNEE, of all right, title, and interest in, to, and deriving from the inventions disclosed in the priority application(s) set forth above by operation offaw, contract, or otherwise.

As far as right, title, and interest of the ASSIGNOR(S) in, to, and deriving from the inventions disclosed in the patent application(s) set forth above may not have been transferred to ASSIGNEE, ASSIGNOR(S) herewith assign(s) to ASSIGNEE all right, title, and interest in, to, and deriving from the invention and to the above priority application(s), including the right to claim priority.

The assignment of the rights of the CO-INVENTOR(S) is subject to a separate assignment agreement. ASSIGNOR(S) explicitly approve(s) that assignment.

ASSIGNEE by virtue of this assignment thereof shall have the exclusive right and is fully entitled to claim priority of the priority application(s) set forth above, to apply for, obtain, and own patents worldwide in its own name and at its own costs that claim priority to and are based in whole or in part on the priority

PATENT REEL: 054106 FRAME: 0319 application(s), to maintain any patent granted thereupon and to discontinue any patents or patent applications as it deems appropriate.

ASSIGNOR(S)

Murray SU-Mar-2020

ASSIGNEE

Roche Diagnostics GmbH

Basel, 16 April 2020

Place, Date

Or Peter Kang Antonio Natoli
Both duly authorized signatories

PATENT REEL: 054106 FRAME: 0320

RECORDED: 08/04/2020